Inactivation of an Anti-CEA Enzyme Conjugate in Blood
Author Information
Author(s): S.K. Sharma, K.D. Bagshawe, P.J. Burke, R.W. Boden, G.T. Rogers
Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital
Hypothesis
Can a new monoclonal antibody effectively inactivate carboxypeptidase G2 in blood while maintaining its therapeutic localization in tumors?
Conclusion
The new monoclonal antibody SB43 can rapidly inactivate carboxypeptidase G2 in blood, improving the safety and effectiveness of enzyme-targeted cancer therapies.
Supporting Evidence
- SB43 can inactivate CPG2 in blood within minutes of administration.
- Galactosylation of SB43 enhances its clearance from circulation.
- The study demonstrated a significant reduction in enzyme activity in blood after SB43 administration.
Takeaway
Scientists created a special antibody that can quickly turn off a cancer-fighting enzyme in the blood, making it safer to use while still helping fight tumors.
Methodology
The study involved in vitro and in vivo experiments using a xenograft model in nude mice to assess the binding and inactivation of CPG2 by the SB43 antibody.
Limitations
The study primarily focused on a specific xenograft model, which may limit the generalizability of the findings to other cancer types.
Participant Demographics
Nude mice bearing human colon adenocarcinoma xenografts.
Want to read the original?
Access the complete publication on the publisher's website